A Phase 1 interventional study of Hyperpolarized 13-C-pyruvate in Ovarian Cancer, sponsored by M.D. Anderson Cancer Center. Suspended at 1 site in United States. Open to female participants aged 18 Months and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by M.D. Anderson Cancer Center · Phase 1, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Ovarian Neoplasms by M.D. Anderson Cancer Center — 15 open to participants now, 31 under way, 1 of them phase 3. Ovarian Neoplasms · M.D. Anderson Cancer Center.
Among the 78 studies in Ovarian Neoplasms by M.D. Anderson Cancer Center, this one is the 30th largest by planned enrollment of the 61 interventional ones that give a count, is the only one that started in 2024, is one of 23 in phase 1, and was the 74th registered.
3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.
Browse Ovarian Neoplasms studies →15 of the 78 studies in Ovarian Neoplasms by M.D. Anderson Cancer Center are open now, in 5 countries. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Women only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Women only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Women only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.
This study: 18 Months and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 27 · Phase 3 1
First in 2001; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 54 across 2,556 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 30 across the 61 interventional studies, 237 across the 17 observational. Of the 39 that completed or were terminated, 14 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
M.D. Anderson Cancer Center is the lead sponsor of 3,051 studies on the registry; 580 are open to participants now.
Of its 614 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.
19 of the studies in Ovarian Neoplasms by M.D. Anderson Cancer Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05287451M.D. Anderson Cancer CenterRisk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study | 2026-12-26 |
| NCT02043158M.D. Anderson Cancer CenterBiobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer | 2026-12-30 |
| NCT05636111M.D. Anderson Cancer CenterPhase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer | 2026-12-31 |
| NCT03579316M.D. Anderson Cancer CenterAdavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | 2026-12-31 |
| NCT05649072M.D. Anderson Cancer CenterIdentifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics. | 2027-02-02 |
Add all 19 to your calendar (.ics) → With an account.
Among the 78 studies in Ovarian Neoplasms by M.D. Anderson Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To learn if an MRSI can be performed on a 3T scanner using an investigational contrast drug called hyperpolarized 13-C pyruvate. 3T refers to the "strength" of the MRI machine.
Primary Objective:
Secondary Objectives:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For the first cohort, the following selection criteria will be applied who are undergoing a screening exam at MD Anderson:
For the third cohort of patients:
10 patients who have suspicion of ovarian on conventional imaging and will be undergoing surgical resection will be included.
Exclusion Criteria:
(all cohorts)
1. Children, pregnant women, cognitively impaired adults, or prisoners will be excluded from participation.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Hyperpolarized 13-C-pyruvate
Given by PO
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 4.03
Time frame: through study completion: an average of 5 years
Started Apr 2024 (actual). Primary completion is estimated for Aug 2028, 52 months after the start.
Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Aug 2028, on Oct 6, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is suspended, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hyperpolarized Carbon C 13 (1-13C) Pyruvate